Inalways - Asset Resilience Ratio
Inalways (5398) has an Asset Resilience Ratio of 9.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 5398 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Inalways's Asset Resilience Ratio has changed over time. See Inalways (5398) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Inalways's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Inalways.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$56.03 Million | 9.33% |
| Total Liquid Assets | NT$56.03 Million | 9.33% |
Asset Resilience Insights
- Limited Liquidity: Inalways maintains only 9.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Inalways Industry Peers by Asset Resilience Ratio
Compare Inalways's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Inalways (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Inalways.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.33% | NT$56.03 Million ≈ $1.77 Million |
NT$600.79 Million ≈ $18.93 Million |
+0.04pp |
| 2024-12-31 | 9.29% | NT$60.65 Million ≈ $1.91 Million |
NT$653.17 Million ≈ $20.58 Million |
+5.17pp |
| 2023-12-31 | 4.12% | NT$22.92 Million ≈ $722.17K |
NT$556.64 Million ≈ $17.54 Million |
+0.37pp |
| 2022-12-31 | 3.75% | NT$22.84 Million ≈ $719.62K |
NT$608.73 Million ≈ $19.18 Million |
-4.68pp |
| 2021-12-31 | 8.43% | NT$54.60 Million ≈ $1.72 Million |
NT$647.84 Million ≈ $20.41 Million |
+1.98pp |
| 2020-12-31 | 6.44% | NT$41.71 Million ≈ $1.31 Million |
NT$647.31 Million ≈ $20.39 Million |
-2.37pp |
| 2019-12-31 | 8.82% | NT$58.96 Million ≈ $1.86 Million |
NT$668.56 Million ≈ $21.06 Million |
-3.87pp |
| 2018-12-31 | 12.69% | NT$79.91 Million ≈ $2.52 Million |
NT$629.72 Million ≈ $19.84 Million |
+7.12pp |
| 2017-12-31 | 5.57% | NT$43.31 Million ≈ $1.36 Million |
NT$777.58 Million ≈ $24.50 Million |
+1.74pp |
| 2016-12-31 | 3.83% | NT$29.43 Million ≈ $927.33K |
NT$769.13 Million ≈ $24.23 Million |
+3.11pp |
| 2015-12-31 | 0.71% | NT$2.45 Million ≈ $77.16K |
NT$343.08 Million ≈ $10.81 Million |
-- |
About Inalways
Mediera Corporation manufactures electronic and power supply components in Taiwan. It is also involved in the medical biotechnology business. The company offers medicines, health food, and medical device, etc. Mediera Corporation was founded in 1967 and is based in New Taipei City, Taiwan.